Will Viking have an approved GLP-1 drug in five years? The big question surrounding Viking Therapeutics today centers around ...

Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares ...

Wells Fargo released its annual biopharma M&A screen this week, including weight loss drug developer Viking Therapeutics ...

Raymond James raised the price target for the Viking Therapeutics Inc (NASDAQ:VKTX) stock from “an Outperform” to “a Strong buy”. The rating was released on May 16, 2024, according to finviz. We ...

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and ...

Breaking this down further, VK2735 might be a $30 billion-a-year drug in the making, depending on how the competitive ...

Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics Inc. shares skyrocketing. But ...

Viking Therapeutics, a clinical-stage company focused on metabolic and endocrine disorders, is primed for acquisition due to its robust pipeline and potential as a market disruptor. The company's ...

Shares of Viking Therapeutics (NASDAQ:VKTX) have surged in the last 12 months, driven by the success of its obesity candidate, the subcutaneously administered VK2735. VK2735’s efficacy ...

Investing in clinical-stage pharmaceutical companies comes with a lot of risk, but also a lot of potential upside. When such a company delivers a successful product that passes regulatory muster ...

Adagio Therapeutics Stock Price latest news, photos, videos, breaking news, special reports, blogs, and updates from Business ...